Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
1.700
+0.040 (2.41%)
At close: Jan 31, 2025, 4:00 PM
1.690
-0.010 (-0.59%)
After-hours: Jan 31, 2025, 4:42 PM EST
Alaunos Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 0.01 | 0.01 | 2.92 | 0.4 | - | - | |
| Revenue Growth (YoY) | -53.33% | -99.83% | 634.17% | - | - | - | |
| Cost of Revenue | 1.38 | 16.28 | 22.52 | 47.28 | 52.7 | 38.33 | |
| Gross Profit | -1.37 | -16.27 | -19.6 | -46.88 | -52.7 | -38.33 | |
| Selling, General & Admin | 6.04 | 12.22 | 13.14 | 26.28 | 27.67 | 19.53 | |
| Operating Expenses | 6.04 | 12.22 | 13.14 | 26.28 | 27.67 | 19.53 | |
| Operating Income | -7.42 | -28.49 | -32.74 | -73.15 | -80.36 | -57.86 | |
| Interest Expense | - | -1.92 | -3.15 | -1.19 | - | - | |
| Other Non Operating Income (Expenses) | 0.23 | 1.05 | 0.53 | -0.01 | 0.39 | 0.81 | |
| EBT Excluding Unusual Items | -7.19 | -29.37 | -35.36 | -74.35 | -79.98 | -57.05 | |
| Merger & Restructuring Charges | -0.85 | -1.27 | - | -3.66 | - | - | |
| Asset Writedown | -3.79 | -4.8 | - | -0.74 | - | - | |
| Other Unusual Items | 0.05 | 0.3 | -2.37 | - | - | -60.75 | |
| Pretax Income | -11.78 | -35.14 | -37.73 | -78.75 | -79.98 | -117.8 | |
| Net Income | -11.78 | -35.14 | -37.73 | -78.75 | -79.98 | -117.8 | |
| Net Income to Common | -11.78 | -35.14 | -37.73 | -78.75 | -79.98 | -117.8 | |
| Shares Outstanding (Basic) | 2 | 2 | 1 | 1 | 1 | 1 | |
| Shares Outstanding (Diluted) | 2 | 2 | 1 | 1 | 1 | 1 | |
| Shares Change (YoY) | 1.88% | 10.50% | 1.27% | 2.27% | 24.82% | 16.87% | |
| EPS (Basic) | -7.36 | -21.97 | -26.07 | -55.10 | -57.22 | -105.20 | |
| EPS (Diluted) | -7.39 | -22.00 | -26.10 | -55.10 | -57.22 | -105.20 | |
| Free Cash Flow | -11.76 | -30.34 | -29.45 | -64.79 | -66.79 | -41.14 | |
| Free Cash Flow Per Share | -7.35 | -18.97 | -20.34 | -45.33 | -47.79 | -36.74 | |
| Operating Margin | -105957.14% | -569860.00% | -1120.40% | -18379.90% | - | - | |
| Profit Margin | -168285.71% | -702800.00% | -1291.24% | -19786.68% | - | - | |
| Free Cash Flow Margin | -168057.14% | -606780.00% | -1007.80% | -16279.15% | - | - | |
| EBITDA | -7.17 | -26.18 | -29.98 | -70.56 | -79.23 | -57.23 | |
| D&A For EBITDA | 0.24 | 2.32 | 2.76 | 2.6 | 1.13 | 0.63 | |
| EBIT | -7.42 | -28.49 | -32.74 | -73.15 | -80.36 | -57.86 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.